Pharma Fridays – June 27, 2025

June 27, 2025

An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Results from AMGEN’S Phase 2 Obesity Study OF Monthly MariTide Presented at The American Diabetes Association 85th Scientific Sessions MariTide, the First Monthly or Less Frequently Dosed Obesity Treatment, Demonstrated Up to ~20% Average Weight Loss Without a Weight Loss Plateau, […]

To view the full Member Resource, please Log in

TOPICS IN THIS ARTICLE:

Pharma Fridays Product / Technology

←Endocrine Society Advocacy in Action – June 2025

Should SGLT2 Inhibitors Be Stopped Before Emergency Surgery?→

View Archives

Join the Global Movement Advancing Endocrine Science and Medicine

Become a part of a community of 18,000-plus endocrine investigators and clinicians who conduct research and provide quality patient care in more than 100 countries. Advance your career and the field of endocrinology through our many educational, leadership and advocacy opportunities.

Join Today